← Leaderboards
Edward E Harlow
Whitehead Institute For Biomedical Res
$6,214,809
Attributed
$6,214,809
Total exposure
9
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $703.1K · FY2006–10$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$6,214,809 · 9
By mechanism
R01$2,440,045 · 3
R21$1,251,282 · 1
P01$1,167,228 · 2
T32$1,041,832 · 1
P30$314,422 · 2
Top collaborators
No co-investigators on record.
Most similar at Whitehead Institute For Biomedical Res
Same institution · by research overlap
- Mark E Ewen$7,974,584
- Daniel J Ehrlich$13,554,899
- Omer Yilmaz$16,106,393
- Benjamin K Chen$29,019,452
- David Altshuler$48,902,164
Others in their field
Top investigators on “Biomedical Facility”
- David Heimbrook · Leidos Biomedical Research, Inc.$269,207,281
- Mark S Klempner · Tufts Medical Center$133,377,807
- Joseph E Robertson · Oregon Health & Science University$129,896,064
- Lee Hamm · Tulane University Of Louisiana$114,986,978
- Peter Gordon Gillespie · Oregon Health And Science University$108,298,240
- Jeffrey S Flier · Beth Israel Deaconess Medical Center$90,163,926
Research focus
Biomedical FacilityOncogenesBreast NeoplasmsLaboratory MouseGene ExpressionMolecular CloningProtein Structure FunctionTransfectionMalignant NeoplasmsMonoclonal AntibodyPhosphorylationProtein KinaseGenetic RegulationMicroinjectionsCell CycleComplementary DnaAnimal Genetic Material TagFundingEvaluationCell TransformationGene MutationDna Binding ProteinEducational Workshop3t3 Cells
Grant awards (27)
How Genetic Variation in Protein Kinases Affects Drug Response$617,816
R21 · FY2010 · MH · contact PI
Planning and Evaluation$65,929
P30 · FY2010 · CA · contact PI
How Genetic Variation in Protein Kinases Affects Drug Response$633,466
R21 · FY2009 · MH · contact PI
Planning and Evaluation$69,617
P30 · FY2009 · CA · contact PI
Planning and Evaluation$65,516
P30 · FY2008 · CA · contact PI
Planning and Evaluation$70,504
P30 · FY2007 · CA · contact PI
Planning and Evaluation$42,856
P30 · FY2006 · CA · contact PI
GENETICS OF CANCER AND INHERITED DISEASES$280,086
T32 · FY2003 · CA
FUNCTION OF THE RETINOBLASTOMA PROTEIN$297,240
R01 · FY2002 · CA
CORE--CDNA ARRAYS$291,807
P01 · FY2002 · CA
CORE--MONOCLONAL ANTIBODIES$291,807
P01 · FY2002 · CA
GENETICS OF CANCER AND INHERITED DISEASES$257,459
T32 · FY2002 · CA
FUNCTION OF THE RETINOBLASTOMA PROTEIN$216,057
R01 · FY2002 · CA
FUNCTION OF THE RETINOBLASTOMA PROTEIN$498,464
R01 · FY2001 · CA
CDC2-RELATED KINASES AND THE CONTROL OF CELL CYCLE$318,857
R01 · FY2001 · CA
CORE--MONOCLONAL ANTIBODIES$291,807
P01 · FY2001 · CA
CORE--CDNA ARRAYS$291,807
P01 · FY2001 · CA
GENETICS OF CANCER AND INHERITED DISEASES$222,254
T32 · FY2001 · CA
CORE--MONOCLONAL ANTIBODIES$0
P01 · FY2001 · CA
CORE--CDNA ARRAYS$0
P01 · FY2001 · CA
FUNCTION OF THE RETINOBLASTOMA PROTEIN$484,060
R01 · FY2000 · CA
ONCOGENE MEDIATED CHANGES IN CELL CYCLE CONTROL$315,694
R01 · FY2000 · CA
CDC2-RELATED KINASES AND THE CONTROL OF CELL CYCLE$309,673
R01 · FY2000 · CA
GENETICS OF CANCER AND INHERITED DISEASES$282,033
T32 · FY2000 · CA
CORE--MONOCLONAL ANTIBODIES$0
P01 · FY2000 · CA
CORE--DEVELOPMENTAL FUNDS$0
P30 · FY2000 · CA
CORE--CDNA ARRAYS$0
P01 · FY2000 · CA